
    
      The "drospirenone 3 mg/ethinylestradiol 20 μg (13 cycles)" group is to be treated by oral
      administration for 52 weeks, 13 cycles. The "drospirenone 3 mg/ethinylestradiol 30 μg (6
      cycles)" group is to be treated by oral administration for 24 weeks, 6 cycles.

      The trial is sponsored by Bayer Yakuhin, Ltd.
    
  